Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 5, 2012, Pages 759-769

  Chen, Jie ^a   Lan, Tian ^b   Hou, Jincai ^c   Zhang, Jingjie ^a   An, Yu ^a   Tie, Lu ^a   Pan, Yan ^a   Liu, Jicheng ^c   Li, Xuejun ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c Medicine and Drug Research Institute   (China)

Author keywords

AKT; Atorvastatin; Carboplatin; Lung cancer; TIMP 1

Indexed keywords

ATORVASTATIN; CARBOPLATIN; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE REPRESSION; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HEPTANOIC ACIDS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84862781764     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.01.015     Document Type: Article

References (35)

1. R. Alessandro, and E.C. Kohn Signal transduction targets in invasion Clin Exp Metastasis 19 2002 265 273 (Pubitemid 34553527)
2. M.J. Arboleda, J.F. Lyons, F.F. Kabbinavar, M.R. Bray, B.E. Snow, and R. Ayala Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells Cancer Res 63 2003 196 206 (Pubitemid 36070440)
3. F. Bernini, A. Poli, and R. Paoletti Safety of HMG-CoA reductase inhibitors: focus on atorvastatin Cardiovasc Drugs Ther 15 2001 211 218 (Pubitemid 33010603)
4. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res 61 2001 3986 3997 (Pubitemid 32720961)
5. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, and V. Serra AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 19 2011 58 71
6. H.H. Chen, T.W. Chen, and H. Lin Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor alpha-regulated heme oxygenase-1 Mol Pharmacol 78 2010 36 45
7. C.F. Cheng, S.H. Juan, J.J. Chen, Y.C. Chao, H.H. Chen, and W.S. Lian Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis Apoptosis 13 2008 883 894
8. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392 (Pubitemid 34270240)
9. O. David, J. Jett, H. LeBeau, G. Dy, J. Hughes, and M. Friedman Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage Clin Cancer Res 10 2004 6865 6871 (Pubitemid 39383035)
10. M.F. Demierre, P.D. Higgins, S.B. Gruber, E. Hawk, and S.M. Lippman Statins and cancer prevention Nat Rev Cancer 5 2005 930 942 (Pubitemid 41766782)
11. G.D. Girnun, L. Chen, J. Silvaggi, R. Drapkin, L.R. Chirieac, and R.F. Padera Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin Clin Cancer Res 14 2008 6478 6486
12. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
13. Y. Jiang, I.D. Goldberg, and Y.E. Shi Complex roles of tissue inhibitors of metalloproteinases in cancer Oncogene 21 2002 2245 2252 (Pubitemid 34311378)
14. V. Khurana, H.R. Bejjanki, G. Caldito, and M.W. Owens Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans Chest 131 2007 1282 1288 (Pubitemid 46762329)
15. W.H. Kim, C.Y. Chon, Y.M. Moon, J.K. Kang, I.S. Park, and H.J. Choi Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines Yonsei Med J 34 1993 45 56 (Pubitemid 23240514)
16. T. Lan, X. Shen, P. Liu, W. Liu, S. Xu, and X. Xie Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway Arch Biochem Biophys 502 2010 112 120
17. M.W. Lee, D.S. Kim, N.Y. Min, and H.T. Kim Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin Int J Cancer 122 2008 2380 2384
18. B. Liu, G. Wang, J. Yang, X. Pan, Z. Yang, and L. Zang Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes PLoS One 6 2011 e21416
19. L.Z. Liu, X.D. Zhou, G. Qian, X. Shi, J. Fang, and B.H. Jiang AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway Cancer Res 67 2007 6325 6332 (Pubitemid 47037515)
20. G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, and B. Snagaski Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin Clin Cancer Res 14 2008 4981 4988
21. S.I. McFarlane, R. Muniyappa, R. Francisco, and J.R. Sowers Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond J Clin Endocrinol Metab 87 2002 1451 1458 (Pubitemid 34615220)
22. I.H. Park, J.Y. Kim, J.I. Jung, and J.Y. Han Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations Invest New Drugs 28 2010 791 799
23. X. Pu, M.A. Hildebrandt, C. Lu, J. Lin, D.J. Stewart, and Y. Ye PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy Lung Cancer 71 2011 82 88
24. C.A. Rabik, and M.E. Dolan Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 33 2007 9 23 (Pubitemid 46137553)
25. R. Ramer, K. Eichele, and B. Hinz Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells Oncogene 26 2007 5822 5827 (Pubitemid 47312810)
26. R. Ramer, and B. Hinz Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1 J Natl Cancer Inst 100 2008 59 69 (Pubitemid 351767340)
27. E. Roudier, O. Mistafa, and U. Stenius Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs Mol Cancer Ther 5 2006 2706 2715 (Pubitemid 44848997)
28. T. Sanli, C. Liu, A. Rashid, S.N. Hopmans, E. Tsiani, and C. Schultz Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression J Thorac Oncol 6 2011 439 450
29. C.M. Shachaf, O.D. Perez, S. Youssef, A.C. Fan, S. Elchuri, and M.J. Goldstein Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood 110 2007 2674 2684 (Pubitemid 47523192)
30. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279 (Pubitemid 37487159)
31. S.G. Spiro, and J.C. Porter Lung cancer - where are we today? Current advances in staging and nonsurgical treatment Am J Respir Crit Care Med 166 2002 1166 1196 (Pubitemid 35222595)
32. G. Tortora, G. di Isernia, C. Sandomenico, R. Bianco, G. Pomatico, and S. Pepe Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells Cancer Res 57 1997 5107 5111 (Pubitemid 27498127)
33. S.D. Westfall, and M.K. Skinner Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment Mol Cancer Ther 4 2005 1764 1771 (Pubitemid 41685311)
34. W.W. Wong, J. Dimitroulakos, M.D. Minden, and L.Z. Penn HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 2002 508 519 (Pubitemid 34460459)
35. X. Yang, M. Fraser, U.M. Moll, A. Basak, and B.K. Tsang Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res 66 2006 3126 3136